Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Victor Jimenez-Zepeda, MD
Videos
Advancements in Treating Patients with Precursor Disorders of Multiple Myeloma
02/24/2025
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD,...
02/24/2025
Oncology
Luciano Costa, MD
Videos
Novel and Updated Therapies for Patients With R/R Multiple Myeloma
02/18/2025
Luciano Costa, MD discusses advancements and updates, including bispecific antibodies and T-cell engagers, for the treatment of patients with R/R multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Luciano Costa, MD discusses advancements and updates, including bispecific antibodies and T-cell engagers, for the treatment of patients with R/R multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Luciano Costa, MD discusses...
02/18/2025
Oncology
Jean-Sébastien Claveau, MD
Conference Coverage
Eliminating Necessity for Sequential Assessment for Progressive Disease Among Patients With Relapsed Multiple Myeloma
01/31/2025
Additional confirmatory tests for progressive disease are not needed to determine progression among patients with MM after 2 biomarkers have met the criteria of progression at the same time, according to a retrospective study.
Additional confirmatory tests for progressive disease are not needed to determine progression among patients with MM after 2 biomarkers have met the criteria of progression at the same time, according to a retrospective study.
Additional confirmatory tests...
01/31/2025
Oncology
Hang Quach, MD, FRACP, FRCPA, MBBS
Videos
Trispecific Antibody Therapy Well-Tolerated Among Patients With Relapsed/Refractory Multiple Myeloma
01/06/2025
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
According to a phase 1 dose...
01/06/2025
Oncology
Meletios-Athanasios Dimopoulos, MD
Videos
Daratumumab Monotherapy Shows Benefit vs Active Monitoring for Patients With High-Risk Smoldering Multiple Myeloma
12/08/2024
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos, MD, discusses findings from the phase 3 Aquila study which demonstrated the benefit of daratumumab monotherapy compared to active monitoring for patients with high-risk smoldering multiple myeloma.
Meletios-Athanasios Dimopoulos,...
12/08/2024
Oncology
Saad Usmani, MD
Conference Coverage
Exploring the Current Treatment Landscape for Patients With Extramedullary MM
10/29/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Saad Usmani, MD, discusses optimal strategies and the current treatment landscape for patients with extramedullary multiple myeloma.
At the 2024 Lymphoma, Leukemia &...
10/29/2024
Lymphoma, Leukemia & Myeloma Network
Mark Bustoros, MD
Conference Coverage
Identifying Unmet Clinical Needs in Treating Patients With Extramedullary MM
10/28/2024
Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
Mark Bustoros, MD, shares expert insight into the unmet clinical needs in targeting and treating patients with extramedullary multiple myeloma, an aggressive subtype of myeloma.
Mark Bustoros, MD, shares expert...
10/28/2024
Lymphoma, Leukemia & Myeloma Network
Bruno Paiva, PhD
Conference Coverage
Exploring the Immune Microenvironment in Multiple Myeloma Treatment
10/25/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Bruno Paiva, PhD, shared expert insight into the immune determinants of response and resistance among patients with multiple myeloma, highlighting the need to bring immune biomarkers into the...
At the 2024 Lymphoma, Leukemia &...
10/25/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD
Conference Coverage
Treatment Options for When Immune Therapies Fail Among Patients With R/R MM
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment possibilities for patients with 
R/R multiple myeloma when immune therapies, such as antibody drug conjugates, CAR T-cell therapy, and bispecific...
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Lymphoma, Leukemia & Myeloma Network

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use